Golden Arrow Merger Corp.
GAMCU
NASDAQ Capital Market8.78
USD
-3.62
- -
CIK
0001841125
ISIN
US3807992058
CUSIP
380799205
Return %
Stock
S&P500
1Y
-16.78
26.57
3Y
-11.22
76.60
5Y
-11.85
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Timothy C. Babich
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 10 East 53rd Street New York City NY United States of America 10022
- IPO Date
- Mar 17, 2021
- CIK
- 0001841125
- Website
- goldenarrowspac.com
- Similar Companies
- Business
- Golden Arrow Merger Corp. (Nasdaq: GAMCU) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing business operations and focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target businesses, primarily in the healthcare and healthcare-related infrastructure industries; it does not currently manufacture or sell products but provides a public market vehicle for such targets in the United States and other developed countries. Incorporated in 2020 and headquartered at 10 E. 53rd Street, 13th Floor, in New York, New York, the company raised $250 million in gross proceeds through its initial public offering of 25 million units in March 2021, with underwriters fully exercising an over-allotment option for additional units, and units trade alongside separated Class A common stock (GAMC) and warrants (GAMCW). In its most significant recent development, Golden Arrow Merger Corp. completed a reverse merger transaction with Bolt Threads Inc. on August 13, 2024, resulting in the formation of Bolt Projects Holdings, Inc. (Nasdaq: BSLK), which trades under a new ticker and advances Bolt Threads' biomaterials platform including b-silk and xl-silk proteins for beauty, personal care, and consumer applications; the deal, initially announced October 4, 2023, at a $346.1 million pro forma enterprise value with $35 million in concurrent financing via PIPE and bridge funding anchored by investors such as Baillie Gifford and Temasek, included extensions of closing deadlines to September 2024 and stockholder approval on August 9, 2024. The transaction integrates Golden Arrow's capital structure with Bolt Threads' intellectual property portfolio of 49 granted patents and 171 pending applications, shifting strategic focus toward sustainable biomaterials while leveraging the SPAC's healthcare expertise from leadership including CEO Timothy Babich and board members from Highline Capital and Stonecourt. Post-merger, Bolt Projects Holdings continues operations from San Francisco, California, targeting growth in consumer sectors with non-toxic, biodegradable alternatives to traditional materials.
Golden Arrow Merger Corp. Announces Full Exercise and Closing of the Underwriters' Over-Allotment Option in Connection with its Initial Public Offering and Separate Trading of its Class A Common Stock and Warrants Commencing on May 7, 2021